

of numeric identifiers and their corresponding definition is provided as Exhibit 2.

This matter was explained on Examiner Moezie's voicemail on May 15, 2001 and we were informed that the application is in fact in proper form as prepared February 14, 2001.

With respect to Matter No. 2 above, on May 10, 2001, we spoke with Mark Spencer from the USPTO Scientific and Technical Center regarding whether or not the prepared non-erred Sequence Listing was successfully forwarded to Examiner Moezie as per our previous instructions. He assured us that he would personally hand deliver the non-erred Sequence Listing to Examiner Moezie.

Respectfully, the Sequence Listing is in proper form.

Respectfully submitted,  
BIERMAN, MUSERLIAN AND LUCAS

Donald C. Lucas  
Donald C. Lucas, 31,275  
Attorney for Applicant(s)  
Tel. # (212) 661-8000

DCL:sd  
Enclosures: Exhibits 1 and 2

SEQUENCE LISTING  
*H1*

<110> SHIMURA, Takesada  
TORIYAMA, Satsuki

<120> CARTILAGE/ BONE INDUCING MATERIALS FOR REPARATION

<130> 146.1286

<140> 09/068,253

<141> 1998-06-09

<150> PCT/JP96/03333

<151> 1996-11-14

<150> JP 7/322402

<151> 1995-11-17

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 357

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(357)

<223> Relevant amino acid residues in SEQ ID NO: 1 from 1 to 119 in WO 95/04819

<300>

<301> HOTTEN, Gertrud  
NEIDHARDT, Helge  
PAULISTA, Michael

<302> NEW GROWTH/DIFFERENTIATION FACTOR OF THE TGF-BETA FAMLY

<310> WO 95/04819

<312> 1995-02-16

<313> 1 TO 119

<400> 1

cca ctg gcc act cgc cag ggc aag cga ccc agc aag aac ctc aag gct 48  
Pro Leu Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala

1

5

10

15

**§ 1.824****37 CFR Ch. I (7-1-00 Edition)**

Numeric identifier	Definition	Comments and format	Mandatory (M) or optional (O).
<10>	Patent Document Number.	Document number, for patent-type citations only. Specify as, for example, US 07/399,999.	O.
<11>	Patent Filing Date	Document filing date, for patent-type citations only; specify as yyyy-mm-dd.	O.
<12>	Publication Date	Document publication date, for patent-type citations only; specify as yyyy-mm-dd.	O.
<13>	Relevant Residues Sequence	FROM (position) TO (position) _____ SEQ ID NO should follow the numeric identifier and should appear on the line preceding the actual sequence.	O.
<400>			M.

[63 FR 29636, June 1, 1998]

**§ 1.824 Form and format for nucleotide and/or amino acid sequence submissions in computer readable form.**

(a) The computer readable form required by § 1.821(e) shall meet the following specifications:

(1) The computer readable form shall contain a single "Sequence Listing" as either a diskette, series of diskettes, or other permissible media outlined in paragraph (c) of this section.

(2) The "Sequence Listing" in paragraph (a) (1) of this section shall be submitted in American Standard Code for Information Interchange (ASCII) text. No other formats shall be allowed.

(3) The computer readable form may be created by any means, such as word processors, nucleotide/amino acid sequence editors or other custom computer programs; however, it shall conform to all specifications detailed in this section.

(4) File compression is acceptable when using diskette media, so long as the compressed file is in a self-extracting format that will decompress on one of the systems described in paragraph (b) of this section.

(5) Page numbering shall not appear within the computer readable form version of the "Sequence Listing" file.

(6) All computer readable forms shall have a label permanently affixed thereto on which has been hand-printed or typed: the name of the applicant, the title of the invention, the date on which the data were recorded on the computer readable form, the operating system used, a reference number, and an application serial number and filing date, if known.

(b) Computer readable form submissions must meet these format requirements:

(1) Computer: IBM PC/XT/AT, or compatibles, or Apple Macintosh;

(2) Operating System: MS-DOS, Unix or Macintosh;

(3) Line Terminator: ASCII Carriage Return plus ASCII Line Feed;

(4) Pagination: Continuous file (no "hard page break" codes permitted);

(c) Computer readable form files submitted may be in any of the following media:

(1) Diskette: 3.50 inch, 1.44 Mb storage; 3.50 inch, 720 Kb storage; 5.25 inch, 1.2 Mb storage; 5.25 inch, 360 Kb storage.

(2) Magnetic tape: 0.5 inch, up to 24000 feet; Density: 1600 or 6250 bits per inch, 9 track; Format: Unix tar command; specify blocking factor (not "block size"); Line Terminator: ASCII Carriage Return plus ASCII Line Feed

(3) 8mm Data Cartridge: Format Unix tar command; specify blocking factor (not "block size"); Line Terminator: ASCII Carriage Return plus ASCII Line Feed.

(4) CD-ROM: Format: ISO 9660 or High Sierra Format

(5) Magneto Optical Disk: Size/Storage Specifications: 5.25 inch, 640 Mb.

(d) Computer readable forms that are submitted to the Office will not be returned to the applicant.

[63 FR 29637, June 1, 1998]

**§ 1.825 Amendments to or replacement of sequence listing and computer readable copy thereof.**

(a) Any amendment to the paper copy of the "Sequence Listing" (§ 1.821(c)) must be made by the submission of substitute sheets. Amendments must

dition)

## Patent and Trademark Office, Commerce

§ 1.823

Numeric identifier	Definition	Comments and format	Mandatory (M) or optional (O).
<110> .....	Applicant .....	Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials.	M.
<120> .....	Title of Invention .....		M.
<130> .....	File Reference .....	Personal file reference .....	M. when filed prior to assignment of appl. number.
<140> .....	Current Application Number .....	Specify as: US 07/999,999 or PCT/US99/99999.	M. if available.
<141> .....	Current Filing Date .....	Specify as: yyyy-mm-dd .....	M. if available.
<150> .....	Prior Application Number .....	Specify as: US 07/999,999 or PCT/US99/99999.	M. if applicable include priority documents under 35 USC 119 and 120.
<151> .....	Prior Application Filing Date .....	Specify as: yyyy-mm-dd .....	M. if applicable.
<160> .....	Number of SEQ ID NOS. .....	Count includes total number of SEQ ID NOS.	M.
<170> .....	Software .....	Name of software used to create the Sequence Listing.	O.
<210> .....	SEQ ID NO.: .....	Response shall be an integer representing the SEQ ID NO shown.	M.
<211> .....	Length .....	Respond with an integer expressing the number of bases or amino acid residues.	M.
<212> .....	Type .....	Whether presented sequence molecule is DNA, RNA, or PROT (protein). If a nucleotide sequence contains both DNA and RNA fragments, the type shall be "DNA." In addition, the combined DNA/RNA molecule shall be further described in the <220> to <223> feature section.	M.
<213> .....	Organism .....	Scientific name, i.e. Genus/ species, Unknown or Artificial Sequence. In addition, the "Unknown" or "Artificial Sequence" organisms shall be further described in the <220> to <223> feature section.	M.
<220> .....	Feature .....	Leave blank after <220>. <221>-<223> provide for a description of points of biological significance in the sequence..	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<221> .....	Name/Key .....	Provide appropriate identifier for feature, preferably from WIPO Standard ST.25 (1996), Appendix 2, Tables 5 and 6.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence.
<222> .....	Location .....	Specify location within sequence; where appropriate state number of first and last bases/amino acids in feature.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence.
<223> .....	Other Information .....	Other relevant information; four lines maximum.	M, under the following conditions: if "n," "Xaa," or a modified or unusual L-amino acid or modified base was used in a sequence; if ORGANISM is "Artificial Sequence" or "Unknown"; if molecule is combined DNA/RNA.
<300> .....	Publication Information .....	Leave blank after <300> .....	O.
<301> .....	Authors .....	Preferably max of ten named authors of publication; specify one name per line; preferable format: Surname, Other Names and/or Initials.	O.
<302> .....	Title .....		O.
<303> .....	Journal .....		O.
<304> .....	Volume .....		O.
<305> .....	Issue .....		O.
<306> .....	Pages .....		O.
<307> .....	Date .....	Journal date on which data published; specify as yyyy-mm-dd, MMM-yyyy or Season-yyyy.	O.
<308> .....	Database Accession Number .....	Accession number assigned by database including database name.	O.
<309> .....	Database Entry Date .....	Date of entry in database; specify as yyyy-mm-dd or MMM-yyyy.	O.